Azafaros announcement

Azafaros announces enrollment of first patient in Phase 2 RAINBOW Study evaluating AZ-3102 in GM2 gangliosidosis and NP-C Patients. RAINBOW study design enables rapid advancement into the company’s planned Phase 3 efficacy trials.

The clinical trial (NCT05758922) is being conducted in Brazil and the US.

Press Release: https://www.azafaros.com/azafaros-announces-enrollment-of-first-patient/